- The FDA has signed off Sorrento Therapeutics Inc's SRNE IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR)-T Cell therapy for relapsed or refractory multiple myeloma.
- DAR-T technology is readily adaptable to dozens of cancer targets, and Sorrento has developed a preclinical product pipeline with specific fully human antibodies discovered from Sorrento's G-MAB library.
- Sorrento expects to file additional IND applications now that the first DAR-T Phase 1 trial has been cleared to proceed by the FDA.
- Price Action: SRNE shares are up 2.98% at $8.47 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
